Release Date: October 23, 2025
Expiration Date: October 23, 2026
Activity Overview
Prostate cancer remains a major clinical challenge, particularly in its advanced stage, when treatment decisions are increasingly complex. In this online, on-demand virtual symposium, renowned experts in prostate cancer participated in case discussions to address key decision points in integrating PSMA imaging and targeted therapies to improve patient outcomes.
This educational activity is an archive of a live symposium held on September 27, 2025.
Target Audience
ASTRO congress attendees, including an audience of radiation oncologists, medical oncologists, advanced practice providers, nurses, and pharmacists involved in the diagnosis and management of patients with prostate cancer
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the diagnostic and prognostic significance of PSMA PET/CT in prostate cancer, and interpret imaging findings to guide radiotherapy planning and clinical decision-making
- Assess recent clinical evidence for PSMA-targeted radioligand therapies, and define the role of radiation oncology in their delivery, monitoring, and coordination
- Design patient-centered strategies for incorporating PSMA-directed radioligand therapy into care pathways, including sequencing and coordination with other specialties
- Identify institutional and logistical barriers to radioligand therapy delivery, and propose solutions to expand access
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here